These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 37513925)

  • 1. Exploring the Molecular Targets for the Antidepressant and Antisuicidal Effects of Ketamine Enantiomers by Using Network Pharmacology and Molecular Docking.
    Altê GA; Rodrigues ALS
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
    Wei Y; Chang L; Hashimoto K
    Mol Psychiatry; 2022 Jan; 27(1):559-573. PubMed ID: 33963284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
    Zhang JC; Yao W; Hashimoto K
    Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arketamine for cognitive impairment in psychiatric disorders.
    Hashimoto K
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1513-1525. PubMed ID: 36786865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
    Hashimoto K
    Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
    Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
    Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.
    Molero P; Ramos-Quiroga JA; Martin-Santos R; Calvo-Sánchez E; Gutiérrez-Rojas L; Meana JJ
    CNS Drugs; 2018 May; 32(5):411-420. PubMed ID: 29736744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats.
    Koncz S; Papp N; Pothorszki D; Bagdy G
    Int J Neuropsychopharmacol; 2023 Sep; 26(9):618-626. PubMed ID: 37578355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.
    Leal GC; Souza-Marques B; Mello RP; Bandeira ID; Caliman-Fontes AT; Carneiro BA; Faria-Guimarães D; Guerreiro-Costa LNF; Jesus-Nunes AP; Silva SS; Lins-Silva DH; Fontes MA; Alves-Pereira R; Cordeiro V; Rugieri-Pacheco S; Santos-Lima C; Correia-Melo FS; Vieira F; Sanacora G; Lacerda ALT; Quarantini LC
    J Affect Disord; 2023 Jun; 330():7-15. PubMed ID: 36871913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antidepressant actions of ketamine and its enantiomers.
    Johnston JN; Henter ID; Zarate CA
    Pharmacol Ther; 2023 Jun; 246():108431. PubMed ID: 37146727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the pharmacological components and effective mechanism of Mori Folium against periodontitis using network pharmacology and molecular docking.
    Wu Z; Ji X; Shan C; Song J; Zhao J
    Arch Oral Biol; 2022 Jul; 139():105391. PubMed ID: 35430443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine for depression clinical issues.
    Iqbal SZ; Mathew SJ
    Adv Pharmacol; 2020; 89():131-162. PubMed ID: 32616205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Mechanisms of Tinglizi against Chronic Heart Failure Determined by Network Pharmacology and Molecular Docking.
    Luo L; Wang H; Huang G; Zhang L; Li X; Ma C; Wang X
    Evid Based Complement Alternat Med; 2022; 2022():2152399. PubMed ID: 35035498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putative Pharmacological Depression and Anxiety-Related Targets of Calcitriol Explored by Network Pharmacology and Molecular Docking.
    Kouba BR; Altê GA; Rodrigues ALS
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023.
    Zhao LY; Zhang GF; Lou XJ; Hashimoto K; Yang JJ
    Eur Arch Psychiatry Clin Neurosci; 2024 Apr; ():. PubMed ID: 38662093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A historical review of antidepressant effects of ketamine and its enantiomers.
    Wei Y; Chang L; Hashimoto K
    Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine in depression and electroconvulsive therapy.
    Rozet I
    Curr Opin Anaesthesiol; 2021 Oct; 34(5):556-562. PubMed ID: 34435599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Network Pharmacology and Molecular Docking Strategy to Explore Potential Targets and Mechanisms Underlying the Effect of Curcumin on Osteonecrosis of the Femoral Head in Systemic Lupus Erythematosus.
    Kang P; Wu Z; Zhong Y; Wang Z; Zhou C; Huo S; Guo H; Li S; Xu K; Liu L; Chen S; Tang H; Wang H
    Biomed Res Int; 2021; 2021():5538643. PubMed ID: 34557547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression.
    Freudenberg F; Reif-Leonhard C; Reif A
    Eur Arch Psychiatry Clin Neurosci; 2024 Aug; ():. PubMed ID: 39207462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.